257 related articles for article (PubMed ID: 37357314)
1. Adipose tissue-derived human mesenchymal stromal cells can better suppress complement lysis, engraft and inhibit acute graft-versus-host disease in mice.
Wu SCM; Zhu M; Chik SCC; Kwok M; Javed A; Law L; Chan S; Boheler KR; Liu YP; Chan GCF; Poon EN
Stem Cell Res Ther; 2023 Jun; 14(1):167. PubMed ID: 37357314
[TBL] [Abstract][Full Text] [Related]
2. Optimization of adipose tissue-derived mesenchymal stem cells by rapamycin in a murine model of acute graft-versus-host disease.
Kim KW; Moon SJ; Park MJ; Kim BM; Kim EK; Lee SH; Lee EJ; Chung BH; Yang CW; Cho ML
Stem Cell Res Ther; 2015 Oct; 6():202. PubMed ID: 26497134
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
[TBL] [Abstract][Full Text] [Related]
4. Chimerism of bone marrow mesenchymal stem/stromal cells in allogeneic hematopoietic cell transplantation: is it clinically relevant?
Miura Y; Yoshioka S; Yao H; Takaori-Kondo A; Maekawa T; Ichinohe T
Chimerism; 2013; 4(3):78-83. PubMed ID: 23880502
[TBL] [Abstract][Full Text] [Related]
5. Umbilical cord blood-derived mesenchymal stromal cells promote myeloid-derived suppressor cell proliferation by secreting HLA-G to reduce acute graft-versus-host disease after hematopoietic stem cell transplantation.
Yang S; Wei Y; Sun R; Lu W; Lv H; Xiao X; Cao Y; Jin X; Zhao M
Cytotherapy; 2020 Dec; 22(12):718-733. PubMed ID: 32811747
[TBL] [Abstract][Full Text] [Related]
6. Extracellular Vesicles Released from Human Umbilical Cord-Derived Mesenchymal Stromal Cells Prevent Life-Threatening Acute Graft-Versus-Host Disease in a Mouse Model of Allogeneic Hematopoietic Stem Cell Transplantation.
Wang L; Gu Z; Zhao X; Yang N; Wang F; Deng A; Zhao S; Luo L; Wei H; Guan L; Gao Z; Li Y; Wang L; Liu D; Gao C
Stem Cells Dev; 2016 Dec; 25(24):1874-1883. PubMed ID: 27649744
[TBL] [Abstract][Full Text] [Related]
7. Reduction of Graft-versus-Host-Disease in NOD.Cg-Prkdc
Hansen M; Stahl L; Heider A; Hilger N; Sack U; Kirschner A; Cross M; Fricke S
Transplant Cell Ther; 2021 Aug; 27(8):658.e1-658.e10. PubMed ID: 33964513
[TBL] [Abstract][Full Text] [Related]
8. Graft-Versus-Host Disease Amelioration by Human Bone Marrow Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles Is Associated with Peripheral Preservation of Naive T Cell Populations.
Fujii S; Miura Y; Fujishiro A; Shindo T; Shimazu Y; Hirai H; Tahara H; Takaori-Kondo A; Ichinohe T; Maekawa T
Stem Cells; 2018 Mar; 36(3):434-445. PubMed ID: 29239062
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S
Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model.
Grégoire C; Ritacco C; Hannon M; Seidel L; Delens L; Belle L; Dubois S; Vériter S; Lechanteur C; Briquet A; Servais S; Ehx G; Beguin Y; Baron F
Front Immunol; 2019; 10():619. PubMed ID: 31001253
[TBL] [Abstract][Full Text] [Related]
11. Perturbations of mesenchymal stromal cells after allogeneic hematopoietic cell transplantation predispose for bone marrow graft-versus-host-disease.
Krüger T; Wehner R; Herbig M; Kräter M; Kramer M; Middeke JM; Stölzel F; List C; Egger-Heidrich K; Teipel R; Oelschlägel U; Wermke M; Jambor H; Wobus M; Schetelig J; Jöhrens K; Tonn T; Subburayalu J; Schmitz M; Bornhauser M; von Bonin M
Front Immunol; 2022; 13():1005554. PubMed ID: 36311725
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
[TBL] [Abstract][Full Text] [Related]
13. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease.
Zhao L; Chen S; Yang P; Cao H; Li L
Stem Cell Res Ther; 2019 Jun; 10(1):182. PubMed ID: 31227011
[TBL] [Abstract][Full Text] [Related]
14. Human mesenchymal stem cells derived from adipose tissue showed a more robust effect than those from the umbilical cord in promoting corneal graft survival by suppressing lymphangiogenesis.
Kang H; Feng J; Peng Y; Liu Y; Yang Y; Wu Y; Huang J; Jie Y; Chen B; He Y
Stem Cell Res Ther; 2023 Nov; 14(1):328. PubMed ID: 37957770
[TBL] [Abstract][Full Text] [Related]
15. Human mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation.
Auletta JJ; Eid SK; Wuttisarnwattana P; Silva I; Metheny L; Keller MD; Guardia-Wolff R; Liu C; Wang F; Bowen T; Lee Z; Solchaga LA; Ganguly S; Tyler M; Wilson DL; Cooke KR
Stem Cells; 2015 Feb; 33(2):601-14. PubMed ID: 25336340
[TBL] [Abstract][Full Text] [Related]
16. Enhanced alleviation of aGVHD by TGF-β1-modified mesenchymal stem cells in mice through shifting MΦ into M2 phenotype and promoting the differentiation of Treg cells.
Wu R; Liu C; Deng X; Chen L; Hao S; Ma L
J Cell Mol Med; 2020 Jan; 24(2):1684-1699. PubMed ID: 31782262
[TBL] [Abstract][Full Text] [Related]
17. CCL1 blockade alleviates human mesenchymal stem cell (hMSC)-induced pulmonary fibrosis in a murine sclerodermatous graft-versus-host disease (Scl-GVHD) model.
Lim JY; Ryu DB; Kim TW; Lee SE; Park G; Yoon HK; Min CK
Stem Cell Res Ther; 2020 Jun; 11(1):254. PubMed ID: 32586381
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial.
Fu H; Sun X; Lin R; Wang Y; Xuan L; Yao H; Zhang Y; Mo X; Lv M; Zheng F; Kong J; Wang F; Yan C; Han T; Chen H; Chen Y; Tang F; Sun Y; Chen Y; Xu L; Liu K; Zhang X; Liu Q; Huang X; Zhang X
BMC Med; 2024 Feb; 22(1):85. PubMed ID: 38413930
[TBL] [Abstract][Full Text] [Related]
19. The efficiency of human umbilical cord mesenchymal stem cells as a salvage treatment for steroid-refractory acute graft-versus-host disease.
Ding Y; Liu C; Cai Y; Hou C; Chen G; Xu Y; Hu S; Wu D
Clin Exp Med; 2023 Oct; 23(6):2561-2570. PubMed ID: 36598673
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
